Historical Impact ATN data drives life-changing decisions ATN 113: PrEPare Studied the safety and use of daily oral PrEP among young people under age 18. Prior to 2018, young people under the age of 18 could not be prescribed PrEP, a critical HIV prevention tool. The findings of this study led to the FDA approving Truvada (TDF/FTC) as a daily oral PrEP option for adolescents.
Future Impact Addressing gaps in STI prevention access ATN 173: foXXy doxy DoxyPEP is effective & approved for use as STI prevention among men, but not for women. The foXXy doxy study hopes to change that. Our findings will provide evidence to inform clinical guidance on DoxyPEP for women. If proven effective, it will add a biomedical resource to women’s STI prevention toolbox and help to bridge a major gap in women's health research.
Learn More About the ATN More studies & findings: atnresearch.org
Check out two ways public health workers in the ATN continue to make an impact, and take a moment to share this post to uplift the #publichealth workers who show up for us every day.
#NPHW2026 #ATNresearch #PrEP #DoxyPEP #HIVprevention #STIprevention #adolescenthealth #research #health
